Millions of cases of adverse drug reactions (ADRs) are reported annually, many of which account for thousands of deaths. This makes the ADRs one of the leading causes of hospitalization and of death in the United States. Knowing the patient’s genetic susceptibility to ADRs is instrumental in preventing serious drug related consequences. An example of a genetic marker associated with ADR is HLA-B*5701 genotype and hypersensitivity to abacavir, used to treat HIV infection. Variants of the HLA genes are reported to be associated with adverse reactions with several therapeutic drugs. To mitigate potentially adverse drug reactions, the FDA recommends testing for HLA typing before administering such drugs.Kashi Clinical Laboratories offers testing of a comprehensive battery of HLA biomarkers. The followings are examples of additional drugs associated with harmful reactions.
Abacavir Hypersensitivity – HLA-B*57:01
Allopurinol – HLA-B*58:01
Carbamazepine Hypersensitivity – HLA-A*31:01 & HLA-B*15:02
Accordion: Phenytoin – HLA-B*15:02
Kashi Clinical Laboratories uses a variety of techniques including Sanger Sequencing, Next Generation Sequencing, and Real-Time PCR to obtain the most reliable result.